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I N T R O D U C T I O N
Obese people have excess body fat. Overweight people have excess weight (weight 
includes bone, fat and muscle). Currently overweight and obesity are defined by body 
mass index (BMI: weight in Kg/height in meters squared, kg/m2). In adults, overweight 
is defined as a BMI of 25-29.9 kg/m2; obesity is defined as a BMI >30 kg/m2. Other 
less commonly used indices, but possibly with more predictive power, include waist 
circumference, waste-to-hip ratio, weight-to-height ratio and body fat.1
Obesity is a highly prevalent metabolic disorder that is increasing in epidemic 
proportions in both children and adults in the United States 2 and the European coun-
tries as well. Obesity is associated with numerous comorbidities, such as dyslipidemia 
hypertension, reduced insulin sensitivity, diabetes mellitus, left ventricular hypertro-
phy, certain cancers and sleep apnea disorder.3-6 Obesity is also an independent risk 
factor for cardiovascular disease (CVD), including hypertension (HTN), coronary 
heart desease (CHD), and heart failure (HF) and is associated with an increased risk 
of morbidity and mortality.7-9
However recent studies have shown that obese people with chronic deseases have 
a better chance of survival than normal-weight individuals do. This finding has been 
called obesity paradox.10,11 The obesity paradox refers to the fact that sometimes being 
heavier -even being overweight or slightly obese- is associated with lower, rather than 
higher, death rates. Severe obesity is consistently, uncontroversially and unparadoxically 
bad for one’s health, and thus it is not going to be part of this discussion.12
‘ O B E S I T Y  P A R A D O X ’  A N D  C A R D I O V A S C U L A R  R I S K 
( P O P U L A T I O N S  W I T H  H E A R T  F A I L U R E ,  C O R O N A R Y 
H E A R T  D I S E A S E  A N D  H Y P E R T E N S I O N )
Although obesity via its negative impact on systolic and diastolic function predis-
poses to overt heart failure (HF), clinical evidence suggests that overweight/obese 
patients with HF paradoxically seem to have a better clinical prognosis than do their 
lean counterparts with clinical HF. Thereafter obesity is a risk factor for developing 
HF (Figure 1), but after the onset of HF, obesity is a positive predictor for survival.13-15 
The existence of this obesity paradox has led physicians to question whether obesity 
should be treated when associated with HF.
Horwich et al41 studied 1,203 individuals with New York Association class IV HF and 
found that higher BMI was associated with better survival (Figure 2) and multivariate 
analysis showed an inverse association between BMI and mortality.
This phenomenon of obesity paradox is also well described in populations with 
coronary heart disease (CHD) and hypertension (HTN).16,17 Despite the negative 
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AbbreviAtions
BMI = body mass index
CABG = coronary artery bypass grafting
CHD = coronary heart disease
CRET = cardiac rehabilitation and 
exercise training
CVD = cardiovascular disease
HF = heart failure
HTN = hypertension
NSTEMI = non-ST elevation myocardial 
infarction
PCI = percutaneous coronary intervention
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grafting-CABG surgery). Recently, in a systematic review of 
40 cohort studies including 250,000 patients during 3.8 years 
of follow up, Romero-Corral et al,17 reported lower total and 
cardiovascular mortality in overweight and obese patients 
with CHD as compared to underweight and normal weight 
individuals. However, in patients with severe obesity (BMI of 
>35 kg/m2), excess risk in cardiovascular mortality was noted 
with no increase in total mortality. These authors concluded 
that the lack of discriminatory power of BMI to differentiate 
between body fat and lean mass could have led to better clinical 
outcomes in overweight and obese patients.17
Another trial examining the glycoprotein IIb/IIIa inhibitor 
abciximab in patients with unstable angina /non-ST-segment 
elevation myocardial infarction (NSTEMI) who were not 
scheduled for coronary intervention showed increased 1- year 
mortality rates in lower –weight patients compared to normal-
weight and obese patients (9.6% in 75-kg group compared with 
7.45 and 6.6% in patients with body weight 75-90 kg and >90 
kg, respectively: p<.001).18 Buettner and colleagues,19 looked 
at the impact of obesity in 1,676 patients with unstable angina/
NSTEMI treated with an early invasive strategy. During 3 years 
of follow-up, there was almost a linear reduction in all-cause 
mortality, from 10% in patients with normal BMI to 8% in 
overweight patients, to 4% in obese patients, to 0% in severely 
obese patients with BMI >35 kg/m2. These findings of better 
prognosis in obese patients with CHD are further supported 
by encouraging evidence from PCI studies and large registries. 
Analysis of the Bypass Angioplasty Revascularization Investi-
gation registry,20 including 2,108 patients who underwent PCI 
and 1,526 patients who underwent CABG, revealed that every 
unit increase in BMI in the PCI group was associated with 6% 
lower risk of in-hospital events, including death, myocardial 
infarction, stroke, and coma. However, in the CABG group, 
there was no impact of BMI on early in-hospital outcomes. 
In contrast, higher BMI was associated with worse long-term 
outcomes in the CABG group but not in the PCI group.20 
However, patients at both extremes, underweight (BMI <18.5 
kg/m2) and extremely obese (BMI >40 kg/m2) had significantly 
higher mortality and higher rates of major adverse cardiac 
events.21
Similarly, studies in populations with HTN have suggested 
better outcomes and better long-term prognosis in obese 
patients. These studies suggest that although obesity is a 
powerful risk factor for HTN and left ventricular hypertrophy, 
obese hypertensive patients have a better prognosis.22 It has 
been postulated that lower systemic vascular resistance and 
lower plasma renin activity in obese hypertensive patients 
compared to leaner hypertensive patients may partly explain 
their improved prognosis.8
This paradoxical association of better prognosis with 
higher BMI was also demonstrated in a population referred 
for echocardiography. The impact of left ventricular (LV) 
geometry and obesity on mortality was assessed in 30,920 
FIgURE 1. Sigma curve showing the probability of heart failure 
as a function of duration of morbid obesity. (Reproduced with 
permission from Alpert MA, Terry BE, Mulekar M, et al. Am J 
Cardiol 1997; 80:736-740.
FIgURE 2. Risk-adjusted survival curves for the 4 body mass 
index categories at 5 years in a study of 1,203 individuals with 
moderate to severe heart failure. Survival was significantly bet-
ter in the overweight and obese categories.
association between higher BMI and CHD, many studies 
suggest paradoxically better prognosis in obese patients with 
CHD and in patients undergoing revascularization (percuta-
neous coronary intervention-PCI, or coronary artery bypass 
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patients with preserved ejection fraction, including 11,792 
obese patients as well as 19,128 non-obese patients during an 
average follow-up of 3.2±1.4 years. Although abnormal LV 
geometric patterns were more commonly observed in obese 
versus non-obese patients (49% vs. 44%, P<.0001), all-cause 
mortality was considerably lower in obese compared to non-
obese patients (3.9% vs. 6.5%, P<.0001). In both obese and 
non-obese patients, there was a progressive increase in mor-
tality with progressive increases in abnormal LV geometry. 
Although in the entire cohort higher BMI was an independent 
predictor of better survival, in the obese subgroup higher BMI 
was associated with higher mortality .We also determined the 
impact of these 2 variables, including LV geometry and obe-
sity, in 8,088 elderly patients (>70 years old) with preserved 
LV function on all-cause mortality during a 3-year follow-up. 
Although abnormal LV geometry progressively increased with 
greater obesity (57%, 59%, and 61%; P<.01 for BMI<25 kg/
m2, BMI of 25–30 kg/m2, and BMI ≥30 kg/m2, respectively), 
total mortality was strongly and inversely related with BMI 
(BMI<18.5 kg/m2, 22% mortality; BMI 18.5–25 kg/m2, 15% 
mortality; BMI 25–30 kg/m2, 10% mortality; BMI 30–35 kg/
m2, 9% mortality; BMI ≥35 kg/m2, 8% mortality).23
U N D E R S T A N D I N g  T H E  M E C H A N I S M S  
O F  T H E  ‘ O B E S I T Y  P A R A D O X ’
The underlying mechanisms for this apparent obesity 
paradox remain elusive. It is postulated that lower body weight 
may be associated with a heightened catabolic state with in-
creasing levels of tumor necrosis factor and other cytokines 
and imbalance in cortisol/dehydroepiandrosterone ratio.6-8 
There is evidence from several studies linking adiposity and 
the natriuretic peptide system; recently, reduced natriuretic 
peptide levels was demonstrated in obese patients with HF.24,25 
This explains the earlier expression of HF with less severe 
symptoms in the presence of obesity secondary to reduced 
circulating natriuretic peptide levels. Therefore, obese patients 
with HF with earlier presentation and less severe symptoms 
receive more aggressive therapy early on, with better long-
term prognosis.24,25
Other lines of evidence suggest enhanced protection 
against endotoxin/inflammatory cytokines with obesity as well 
as increased nutritional and metabolic reserves.26,27 Evidence 
from basic science studies suggests that adipose tissue is 
occupied with dense soluble tumor necrosis factor α recep-
tors, which have a neutralizing effect on cytokines, including 
interleukin 1 and tumor necrosis factor α, and might have a 
protective role in obese patients with acute or chronic HF.28 
Also, just being obese with good nutritional and metabolic 
reserves might confer favorable prognosis in both obese pa-
tients with HF and CHD alike. Obese patients with HF have 
lower baseline levels of the renin-angiotensin system, which 
might protect the cardiovascular system from their deleterious 
effects.29, 30 Because obese patients have higher blood pressure 
levels, they might better tolerate cardioprotective medications 
and have a better prognosis.26 Nevertheless, despite these 
potential mechanisms, the exact reasons for these puzzling 
results remain elusive. In addition, most of these studies have 
focused on BMI and a few on percentage of body fat, and 
there is little information regarding other parameters (eg, 
waist circumference, waist-to-hip ratio) in the obesity paradox.6 
Finally, many of the studies did not adjust for smoking and 
chronic obstructive pulmonary disease among underweight 
and leaner subjects, as well as nonpurposeful weight loss in 
the participants, which may suggest worse prognosis for almost 
every potential etiology.31
W E I g H T  L O S S
Studies looking at the impact of weight reduction in over-
weight and obese cardiac patients have been controversial, 
some suggesting better clinical outcomes, whereas others 
indicating no benefits and, in fact, some studies have even 
suggested detrimental effects. However, other studies assessing 
mortality based on lean body mass and total body fat content as 
opposed to BMI showed that losing body fat rather than lean 
mass has mortality benefits.6 In a study of 74 morbidly obese 
patients, Alpert et al,32 showed that significant weight reduction 
>30% of total body weight with gastroplasty (12 of 14 morbidly 
obese patients achieved this weight loss) resulted in improve-
ment of New York Heart Association functional class by an 
average of >1. In this study, weight loss was also associated 
with marked improvements in left ventricular dimensions and 
systolic function. Mac Mahon et al, 33 demonstrated that even 
minimal weight loss of 8 kg or 17.6 lb in mildly obese subjects 
with HTN was associated with significantly greater reductions 
in left ventricular mass and wall thickness compared to reduc-
tions achieved in subjects treated with pharmacologic therapy 
with β-blockers. Among various nonpharmacologic means of 
weight reduction, cardiac rehabilitation and exercise training 
(CRET) is the most extensively studied method. In one particu-
lar study (from the Ochsner Clinic Foundation) with patients 
with metabolic syndrome, CRET led to a 37% reduction in the 
prevalence of metabolic syndrome.34 In a small subgroup of 
45 obese patients with CHD from the CRET program, it was 
demonstrated that even small reductions in body weight (>5% 
or more; average, 10%) were associated with marked improve-
ments in obesity indices, lipids, and exercise capacity when 
compared to the cohort that did not lose weight.35 Recently, 
marked reductions in C-reactive protein levels were noted 
in obese patients with CHD following CRET, whereas lean 
patients had nonsignificant reductions in C-reactive protein.36 
In a preliminary analysis of a much larger sample size, marked 
improvements were noted in CHD risk factors, including C-
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reactive protein, lipids, and glucose, among patients with CHD 
who lost weight; this group had a trend for lower mortality.16 
Therefore, these data do not indicate that obesity should be 
ignored as a risk factor just because an obesity paradox exists. 
In fact, obesity remains a powerful risk factor for the develop-
ment of HTN, HF, and CHD, and it is believed that purposeful 
weight reduction should still be emphasized, particularly for 
the more obese patients with HTN, HF, and CHD, despite 
the obesity paradox. Additionally, marked weight loss with 
bariatric surgery has resulted in improved mortality risk, mostly 
related to diabetes mellitus, cancers, and CVD events.37-40 
Although data are limited on the efficacy and safety of these 
procedures in patients with established CVD, a recent study in 
12 patients with severe HF41 suggests safety and improvements 
in HF prognosis following this surgery that may be considered 
to be high risk in patients with HF.
On the other hand, a most recent study, which was pub-
lished online (16/1/2014, Am J Public Health), found that 
obesity was associated with at least a 20% increased risk of 
death from all causes or from heart disease. Overall, obese 
adults died 3.7 years earlier from all causes and 1.7 years ear-
lier from heart disease compared with normal-weight adults. 
In the study researches said: The authors suggest that ‘‘Given 
the prevalence of obesity among children and young adults, 
early intervention is absolutely essential in order to prevent 
this trend from increasing exponentially as these populations 
continue to age’’.
O B E S I T Y  A N D  D I A B E T E S
Recent studies suggesting that heavier people with diabetes 
have lower death rates than normal weight patients may be a 
myth! A strong body of research shows that being overweight 
or obese puts people at risk for chronic conditions like heart 
disease, diabetes, cancer and even early death. But several 
small studies connecting obesity to a protective effect against 
type 2 diabetes-related death have raised questions about a 
possible ‘obesity paradox,’ and whether weight can be a benefit 
in preventing progression of the disease.
A 2012 study published in JAMA, for example, studied 
2,625 people recently diagnosed with type 2 diabetes, of 
whom only 12% had normal weight. But the larger people 
with diabetes lived longer than their thinner peers. Why the 
heavier people lived longer was not clear; the researchers 
speculated that genetics, or the type of fat that certain obese 
people accumulated compared to normal weight individuals 
could be responsible.
However, in a new study published in the New England 
Journal of Medicine, scientists say that this is unlikely. “We 
didn’t see this protective effect at all,” the study’s leader, 
Diedre Tobias of the Harvard School of Public Health, told: 
“The lowest risk was seen in the normal-weight category.” 
Tobias and her colleagues looked at 11,427 female nurses and 
male health professionals who were diagnosed with diabetes. 
They were divided into groups based on their BMI, with those 
with a BMI over 25 considered overweight and people with a 
BMI over 30 considered obese. After 15 years, the scientists 
recorded the participants’ death rates and found that those 
with BMI in the 22.5 to 25 range, considered normal weight, 
had the lowest risk of diabetes-related death.
However, whereas ‘overweight’ implies increased risk, it is 
in fact associated with decreased mortality risk compared with 
normal weight.42 Another paradox concerns the observation 
than when fitness is taken into account, the mortality risk as-
sociated with obesity is offset. The final paradox under consid-
eration is the presence of a sizeable subset of obese individuals 
who are otherwise healthy. Consequently, a large segment of 
the overweight and obese population is not at increased risk 
for premature death. It appears therefore that low cardiores-
piratory fitness and inactivity are a greater health threat than 
obesity, suggesting that more emphasis should be placed on 
increasing leisure time physical activity and cardiorespiratory 
fitness as the main strategy for reducing mortality risk in the 
broad population of overweight and obese adults.43
C O N C L U S I O N S
Obesity is independently associated with the incidence 
of new CHD cases and adversely affects conventional CHD 
risk factors, including HTN, diabetes mellitus, dyslipidemia, 
and the metabolic syndrome.This negative relationship be-
came more evident as accumulated evidence from long-term 
follow-up studies found that obesity was associated with CHD, 
independent of other cardiovascular risk factors. Data from 
the Pathobiological Determinants of Atherosclerosis in Youth 
study suggest that overweight and obesity in young adults ac-
celerate the progression of atherosclerosis decades before the 
appearance of clinical manifestations. Prospective studies that 
reported follow-up data for more than 2 decades, such as the 
Manitoba Study, the Framingham Heart Study, and the Har-
vard School of Public Health Nurses Study, have documented 
that obesity is an independent predictor of clinical CHD.
Although obesity is a risk factor for the pathogenesis and 
progression of CVD, evidence reports the existence of an 
obesity paradox, in that obese patients with established CVD 
appear to have a better clinical prognosis. Available evidence 
supports the benefits of purposeful weight reduction in curbing 
the obesity pandemic and associated CVD. Further research is 
needed to better understand the puzzling obesity paradox phe-
nomenon, the underlying mechanisms for the phenomenon, 
and weight reduction strategies in various subgroups and to 
better define the optimal weight in these special populations of 
high-risk patients with and without established CVD to better 
manage these complicated cases.
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